Fianlimab clinical trials
Also written REGN3767.
How each study uses fianlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fianlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2026 (9); 1 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2016 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 13
Regeneron Pharmaceuticals (10) · Memorial Sloan Kettering Cancer Center (3) · John Strickler, M.D. (1) · University of California, Irvine (1) · M.D. Anderson Cancer Center (1) · Brian Rini (1) · Mayo Clinic (1) · Intergroupe Francophone de Cancerologie Thoracique (1)
Often tested with
Tested in the same studies.
Cemiplimab (16) · Ipilimumab (1) · Trastuzumab (1) · Ganitumab (1) · Ado-Trastuzumab Emtansine (1) · Pertuzumab (1) · STA 9090 (1) · Veliparib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 3 in phase 3
Studies that test fianlimab, phase 3 first.
- Jan 2027A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryPhase 3 · Regeneron Pharmaceuticals
- Mar 2027A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Phase 3 · Regeneron Pharmaceuticals
- Sep 2027A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)Phase 2/3 · Regeneron Pharmaceuticals
- Sep 2027A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaPhase 2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses fianlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)RecruitingPhase 2Brian RiniNCT07188896Written as Fianlimab
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingPhase 3Regeneron PharmaceuticalsNCT06246916Written as fianlimab
- Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon CancerNot yet recruitingPhase 2John Strickler, M.D.NCT07224022Written as Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
- Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung CancerRecruitingPhase 2Mayo ClinicNCT06918132Written as Fianlimab
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Regeneron PharmaceuticalsNCT06769698Written as FDC fianlimab+cemiplimab
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06594991Written as Fianlimab
- Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanomaNot yet recruitingPhase 2University of California, IrvineNCT07527325Written as Fianlimab
- Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaRecruitingPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT07234058Written as Fianlimab
- A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After TreatmentRecruitingPhase 2University of ChicagoNCT07179315Written as cemiplimab+fianlimab
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Cemiplimab plus REGN3767
- A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A EpendymomaNot yet recruitingPhase 1/2Regeneron PharmaceuticalsNCT07567469Written as Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
- PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable MelanomaNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07511036Written as Fianlimab
- A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell CarcinomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06699602Written as Fianlimab
- Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaRecruitingPhase 2University of OklahomaNCT07223541Written as Fianlimab 1600 MG Intravenous Solution
- Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain MetastasesRecruitingPhase 2Grupo Español Multidisciplinar de MelanomaNCT06887088Written as cemiplimab+fianlimab
- A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryActive, not recruitingPhase 3Regeneron PharmaceuticalsNCT05608291Written as Fianlimab
- A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentActive, not recruitingPhase 2Regeneron PharmaceuticalsNCT06848088Written as Fianlimab+cemiplimab
- A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder CancerWithdrawnPhase 2Memorial Sloan Kettering Cancer CenterNCT07414992Written as Cemiplimab and Fianlimab
- A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryActive, not recruitingPhase 2Regeneron PharmaceuticalsNCT06161441Written as Fianlimab
- A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung CancerActive, not recruitingPhase 2/3Regeneron PharmaceuticalsNCT05800015Written as fianlimab
See all 23 studies that test fianlimab →
Given beside what is tested · 15 — fianlimab is usual care or a partner of the new treatment
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRecruitingPhase 2Regeneron PharmaceuticalsNCT06787612Written as Fianlimab
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Fianlimab
- A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal CarcinomaNot yet recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07650266Written as Fianlimab
- A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)Not yet recruitingPhase 2Regeneron PharmaceuticalsNCT07808515Written as Fianlimab
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabRecruitingPhase 1/2Regeneron PharmaceuticalsNCT04590326Written as Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
- Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07281768Written as Fianlimab
- Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06205836Written as Fianlimab
- Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung CancerRecruitingPhase 2Montefiore Medical CenterNCT06865339Written as Fianlimab
- A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and NeckNot yet recruitingPhase 2University of ChicagoNCT07346196Written as Fianlimab
- Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)TerminatedPhase 2Columbia UniversityNCT06571708Written as Fianlimab
- Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate CancerActive, not recruitingPhase 1/2University of Wisconsin, MadisonNCT04989946Written as Fianlimab
- Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before SurgerySuspendedPhase 2Thomas Jefferson UniversityNCT05929664Written as Fianlimab
- Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsActive, not recruitingPhase 2Regeneron PharmaceuticalsNCT03916627Written as fianlimab
- Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced MalignanciesActive, not recruitingPhase 1Regeneron PharmaceuticalsNCT03233139Written as Fianlimab
- Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)WithdrawnPhase 2Regeneron PharmaceuticalsNCT06384820Written as fianlimab
As the comparator · 1 — what is tested is compared with fianlimab
Codes
What other systems call fianlimab · ClinicalTrials.gg INT017509
- UNII (FDA) OX5LRQ5H6KFIANLIMABOne source FDA
- NCI Thesaurus C132339FianlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OX5LRQ5H6K | FIANLIMAB | One source FDA |
| NCI Thesaurus | C132339 | Fianlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.